<DOC>
	<DOCNO>NCT02641873</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 study BBI608 combination FOLFIRI + Bavacizumab . This study population adult Japanese patient metastatic colorectal cancer FOLFIRI + Bevacizumab combination therapy .</brief_summary>
	<brief_title>A Study BBI608 Administrated With FOLFIRI + Bevacizumab Adult Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . A histologically confirm advanced unresectable , metastatic recurrent colorectal carcinoma 2 . Evaluable patient RECISTversion 1.1 3 . Stage IV 4 . ≥ 20 year age 5 . Life expectancy ≥ 3 month . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 7 . Patients follow organ function within 14 day enrollment ( basis recent data period multiple data available ) Hemoglobin ( Hg ) ≥ 9.0 g/dL Neutrophil count ≥ 1.5 x 103/μL Platelet count ≥ 10 x 104/μL Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 × institutional upper limit normal ( ULN ) [ ≤ 5 × ULN presence liver metastases ] Total bilirubin ≤ 1.5 × institutional ULN [ ≤ 2 × ULN presence liver metastases ] Creatinine ≤ 1.5 × institutional ULN Proteinuria dipstick urine analysis ≤ 1+ . [ UPCR ( Urine AlbumintoCreatinine Ratio ) ≤ 1 , protein volume 24hour urine collection ≤ 1 g , case patient 2+ urine dipstick read ] 8 . For female patient child produce potential : Must agree use contraception take measure avoid pregnancy study 30 day last protocol treatment dose 6 month Bevacizumab treatment.. For male patient child produce potential : Must agree use contraception take measure avoid pregnancy study 90 day last protocol treatment dose 6 month Bevacizumab treatment 9 . Females childbearing potential negative urine pregnancy test 10 . Patients provide write voluntary consent person participate study fully receive understand information study , include study 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , hormone therapy , heart therapy within 21 day first dose BBI608 2 . Major surgery within 28 day prior first dose 3 . Have brain metastasis symptom require treatment 4 . Have coinstantaneously active multiple primary cancer 5 . Have carcinomatous pleural effusion , ascites , cardiac effusion require treatment 6 . Crohn 's disease , ulcerative colitis , small intestine resection , diarrhea ( watery diarrhea ) , paralysis intestinal , Intestinal obstruction 7 . Gastrointestinal perforation , tracheooesophageal fistula , fistula 8 . Unable unwilling swallow BBI608 capsule 9 . Uncontrolled intercurrent illness ( Grade 3 active infection , serious respiratory disease ) 10 . Uncontrolled hypertension 11 . Patients recent history hemoptysis 2.5 mL red blood within 28days enrolment 12 . Abnormal ECGs clinically significant within 28 day enrolment 13 . Patients New York Heart Association ( NYHA ) functional class III , IV , unstable angina 14 . Patients newly express angina within three month ( 90 day ) enrolment 15 . Have myocardial infarction within six month ( 180 day ) enrolment 16 . Administrating antiarrhythmic drug 17 . Patients plan breastfeed whichever 30 day last administration BBI608 6 month last administration Bevacizumab 18 . Patients pregnancy possibility pregnancy current time possibility pregnancy within 6 month last administration Bevacizumab 19 . Have receive investigational product finish assessment clinical study within 28 day enrollment 20 . Known severe hypersensitivity 5FU/ levofolinate/ irinotecan/Bevacizumab 21 . Administration atazanavir sulfate 22 . Prior treatment BBI608 23 . Ineligible participation study opinion Investigators</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic Colorectal Cancer</keyword>
	<keyword>mCRC</keyword>
</DOC>